These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20529987)

  • 1. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
    Mangla R; Singh G; Ziegelitz D; Milano MT; Korones DN; Zhong J; Ekholm SE
    Radiology; 2010 Aug; 256(2):575-84. PubMed ID: 20529987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
    Niyazi M; Schwarz SB; Suchorska B; Belka C
    Strahlenther Onkol; 2012 Feb; 188(2):154-9. PubMed ID: 22231634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
    Rock K; McArdle O; Forde P; Dunne M; Fitzpatrick D; O'Neill B; Faul C
    Br J Radiol; 2012 Sep; 85(1017):e729-33. PubMed ID: 22215883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
    Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
    J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
    Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
    Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
    J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
    Grossman SA; Ye X; Piantadosi S; Desideri S; Nabors LB; Rosenfeld M; Fisher J;
    Clin Cancer Res; 2010 Apr; 16(8):2443-9. PubMed ID: 20371685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
    Sanghera P; Perry J; Sahgal A; Symons S; Aviv R; Morrison M; Lam K; Davey P; Tsao MN
    Can J Neurol Sci; 2010 Jan; 37(1):36-42. PubMed ID: 20169771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
    Joo JD; Kim H; Kim YH; Han JH; Kim CY
    J Korean Med Sci; 2015 Nov; 30(11):1597-603. PubMed ID: 26539003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
    Nachbichler SB; Schupp G; Ballhausen H; Niyazi M; Belka C
    Strahlenther Onkol; 2017 Nov; 193(11):890-896. PubMed ID: 28197654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time trends in glioblastoma multiforme survival: the role of temozolomide.
    Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
    Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
    Scoccianti S; Magrini SM; Ricardi U; Detti B; Buglione M; Sotti G; Krengli M; Maluta S; Parisi S; Bertoni F; Mantovani C; Tombolini V; De Renzis C; Lioce M; Fatigante L; Fusco V; Muto P; Berti F; Rubino G; Cipressi S; Fariselli L; Lupattelli M; Santoni R; Pirtoli L; Biti G
    Neurosurgery; 2010 Aug; 67(2):446-58. PubMed ID: 20644432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
    Gunjur A; Bressel M; Ryan G
    J Med Imaging Radiat Oncol; 2012 Oct; 56(5):567-73. PubMed ID: 23043578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
    Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
    Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.
    Lee EK; Choi SH; Yun TJ; Kang KM; Kim TM; Lee SH; Park CK; Park SH; Kim IH
    Korean J Radiol; 2015; 16(6):1341-8. PubMed ID: 26576125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of patients with multifocal glioblastoma: a case-control study.
    Patil CG; Yi A; Elramsisy A; Hu J; Mukherjee D; Irvin DK; Yu JS; Bannykh SI; Black KL; Nuño M
    J Neurosurg; 2012 Oct; 117(4):705-11. PubMed ID: 22920963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.